Fluzoparib Monotherapy

DRUG3 trials

Sponsors

Xiaohua Wu MD, Tongji Hospital, Tianjin Medical University Cancer Institute and Hospital

Conditions

BRCA1/2 Mutation or NotOvarian CancerPlatinum-sensitiveRelapsed Ovarian CancerTNBC, Triple Negative Breast Cancer

Phase 2

Fluzoparib and Apatinib Versus Fluzoparib in Relapsed Ovarian Carcinoma Maintenance Treatment

Not yet recruitingNCT05479487

Xiaohua Wu MDRelapsed Ovarian Cancer

Start: 2022-08-01End: 2026-09-01Target: 132Updated: 2022-07-29

A Single-Arm Phase Ⅱ Study of Fluzoparib Maintenance in Platinum-sensitive Advanced Triple-Negative Breast Cance

RecruitingNCT07321015

Tianjin Medical University Cancer Institute and HospitalBRCA1/2 Mutation or Not, Platinum-sensitive, TNBC, Triple Negative Breast Cancer

Start: 2026-01-20End: 2027-11-30Target: 72Updated: 2026-08-21

Phase 3

Fluzoparib+Bevacizumab/Dietary Intervention vs Fluzoparib Monotherapy as First-line Maintenance in HRD+/- Advanced Ovarian Cancer

RecruitingNCT06954584

Tongji HospitalOvarian Cancer

Start: 2025-05-27End: 2032-03-01Target: 424Updated: 2025-06-24